Brief: FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3
09/12/2024 13:41
Dec 9 (Reuters) - Acurx Pharmaceuticals ACXP.O :
* ACURX UPDATES PHASE 3 READINESS FOR IBEZAPOLSTAT IN C.
DIFFICILE
INFECTION BASED ON RECENT FDA AND EMA COMMUNICATIONS
* ACURX PHARMACEUTICALS INC - FDA PROVIDES POSITIVE FEEDBACK
ON
ACURX'S CMC PLAN FOR PHASE 3
Source text: ID:nPn6PDJra
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program